Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 14/20 | 0.37 |
| ▸ | GUCY1B1 | Q02153 | 14/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516959 | 0.89 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1KCNH2PTPN11ADORA3 | |
| SCHEMBL517421 | 0.88 | GUCY1A1 (0.44) | GUCY1A1GUCY1B1KCNH2PTPN11 | |
| SCHEMBL15378024 | 0.81 | GUCY1A1 (0.34) | GUCY1A1GUCY1B1KCNH2PTPN11HCRTR1 | |
| SCHEMBL516268 | 0.81 | PTPN11 (0.37) | GUCY1A1GUCY1B1KCNH2PTPN11HCRTR1 | |
| SCHEMBL7909556 | 0.80 | GUCY1A1 (0.36) | GUCY1A1GUCY1B1KCNH2PTPN11 | |
| SCHEMBL516308 | 0.79 | GUCY1A1 (0.42) | GUCY1A1GUCY1B1KCNH2PTPN11 | |
| SCHEMBL7905090 | 0.79 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1KCNH2PTPN11ADORA3 | |
| SCHEMBL515093 | 0.77 | NPY1R (0.38) | PTPN11MAPT | |
| SCHEMBL516306 | 0.75 | GUCY1A1 (0.52) | GUCY1A1GUCY1B1KCNH2PTPN11 | |
| SCHEMBL16534555 | 0.73 | GUCY1A1 (0.51) | GUCY1A1GUCY1B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | GUCY1A1 3203/4885GUCY1B1 2537/4885KCNH2 302/4885 |
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | GUCY1A1 3203/4885GUCY1B1 2537/4885KCNH2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.